Association of CYP2C19*2 Polymorphism with Clopidogrel Response and 1-year Major Adverse Cardiovascular Events in A Multiethnic Population with Drug-Eluting Stents

References

• Steinhubl SR , BergerPB , MannIJet al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial . JAMA288 ( 19 ), 2411 – 2420 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , AntmanEM . Clopidogrel resistance: a new chapter in a fast-moving story . Circulation109 ( 25 ), 3064 – 3067 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Ma TK , LamYY , TanVP , YanBP . Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?Br. J. Clin. Pharmacol.72 ( 4 ), 697 – 706 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Holmes MV , PerelP , ShahT , HingoraniAD , CasasJP . CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis . JAMA306 ( 24 ), 2704 – 2714 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Harmsze AM , Van WerkumJW , Ten BergJMet al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study . Eur. Heart J.31 ( 24 ), 3046 – 3053 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Oh IY , ParkKW , KangSHet al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents . Heart98 ( 2 ), 139 – 144 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Scott SA , SangkuhlK , SteinCMet al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update . Clin. Pharmacol. Ther.94 ( 3 ), 317 – 323 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Shuldiner AR , O’ConnellJR , BlidenKPet al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy . JAMA302 ( 8 ), 849 – 857 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Simon T , VerstuyftC , Mary-KrauseMet al. Genetic determinants of response to clopidogrel and cardiovascular events . N. Engl. J. Med.360 ( 4 ), 363 – 375 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Fintel DJ . Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options . Vasc. Health Risk Manag.8 , 77 – 89 ( 2012 ).
   PubMedGoogle Scholar
• Freedman JE . The aspirin resistance controversy: clinical entity or platelet heterogeneity?Circulation113 ( 25 ), 2865 – 2867 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Chadha DS , SumanaB , KarthikeyanG , JayaprasadV , ArunSS . Prevalence of aspirin resistance in Asian-Indian patients with stable coronary artery disease . Catheter. Cardiovasc. Interv.88 ( 4 ), E126 – E131 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Von Pape KW , Dzijan-HornM , BohnerJ , SpannaglM , WeisserH , CalatzisA . [Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and multiplate] . Hamostaseologie27 ( 3 ), 155 – 160 ; Quiz 161–152 ( 2007 ).
   PubMedGoogle Scholar
• Mejin M , TiongWN , LaiLYet al. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention . Int. J. Clin. Pharm.35 ( 4 ), 621 – 628 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Sibbing D , BraunS , JawanskySet al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment . Thromb. Haemost.99 ( 1 ), 121 – 126 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Gurbel PA , BeckerRC , MannKG , SteinhublSR , MichelsonAD . Platelet function monitoring in patients with coronary artery disease . J. Am. Coll. Cardiol.50 ( 19 ), 1822 – 1834 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Sibbing D , BraunS , MorathTet al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis . J. Am. Coll. Cardiol.53 ( 10 ), 849 – 856 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Thygesen K , AlpertJS , WhiteHDet al. Universal definition of myocardial infarction . Circulation116 ( 22 ), 2634 – 2653 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Laskey WK , YancyCW , MaiselWH . Thrombosis in coronary drug-eluting stents: report from the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7–8, 2006 . Circulation115 ( 17 ), 2352 – 2357 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Mehran R , RaoSV , BhattDLet al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium . Circulation123 ( 23 ), 2736 – 2747 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Rodriguez S , GauntTR , DayIN . Hardy–Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies . Am. J. Epidemiol.169 ( 4 ), 505 – 514 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Dupont WD , PlummerWD . Power and sample size calculations for studies involving linear regression.Controlled Clinical Trials19 , 589 – 601 ( 1998 ).
   PubMedGoogle Scholar
• Chan MY . Clopidogrel pharmacogenetics of east, south and other Asian populations . Eur. Heart J. Suppl.14 ( Suppl. A ), A41 – A42 ( 2012 ).
   Web of Science ®Google Scholar
• Nasyuhana Sani Y , Sheau ChinL , Luen HuiLet al. The CYP2C19*1/*2 genotype does not adequately predict clopidogrel response in healthy Malaysian volunteers . Cardiol. Res. Pract. 2013 , 7 ( 2013 ).
   Google Scholar
• Umemura K , FurutaT , KondoK . The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects . J. Thromb. Haemost.6 ( 8 ), 1439 – 1441 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Sibbing D , StegherrJ , LatzWet al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention . Eur. Heart J.30 ( 8 ), 916 – 922 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Mega JL , SimonT , ColletJPet al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis . JAMA304 ( 16 ), 1821 – 1830 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Galloe AM , ThuesenL , KelbaekHet al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial . JAMA299 ( 4 ), 409 – 416 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Jensen LO , MaengM , KaltoftAet al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions . J. Am. Coll. Cardiol.50 ( 5 ), 463 – 470 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Park S-J , KimY-H . Current status of percutaneous coronary intervention with drug-eluting stents in Asia . Circulation118 ( 25 ), 2730 – 2737 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Zhang YJ , LiMP , TangJ , ChenXP . Pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives . Int. J. Environ. Res. Public Health14 ( 3 ), pii: E301 ( 2017 ).
   Web of Science ®Google Scholar
• Li M , WangH , XuanLet al. Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome . Medicine (Baltimore)96 ( 14 ), e6553 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Shuldiner AR , O’ConnellJR , BlidenKPet al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy . JAMA302 ( 8 ), 849 – 857 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Gurbel PA , AntoninoMJ , BlidenKPet al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target . Platelets19 ( 8 ), 595 – 604 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Gurbel PA , BlidenKP , HiattBL , O’ConnorCM . Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity . Circulation107 ( 23 ), 2908 – 2913 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Gurbel PA , BlidenKP , SamaraWet al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study . J. Am. Coll. Cardiol.46 ( 10 ), 1827 – 1832 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Migliorini A , ValentiR , MarcucciRet al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease . Circulation120 ( 22 ), 2214 – 2221 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Patti G , NuscaA , MangiacapraF , GattoL , D’AmbrosioA , Di SciascioG . Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study . J. Am. Coll. Cardiol.52 ( 14 ), 1128 – 1133 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , ShoemakerSB , DesaiBet al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study . Circulation115 ( 6 ), 708 – 716 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Matetzky S , ShenkmanB , GuettaVet al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction . Circulation109 ( 25 ), 3171 – 3175 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Breet NJ , Van WerkumJW , BoumanHJet al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation . JAMA303 ( 8 ), 754 – 762 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM , Delle-KarthG , LangIMet al. Phenotyping vs genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study . J. Thromb. Haemost.10 ( 4 ), 529 – 542 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Gori AM , MarcucciR , MiglioriniAet al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents . J. Am. Coll. Cardiol.52 ( 9 ), 734 – 739 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd , FurmanMI , LindenMDet al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700 patient study of aspirin resistance . Circulation113 ( 25 ), 2888 – 2896 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Wang X , GongX , ZhuTet al. Clopidogrel improves aspirin response after off-pump coronary artery bypass surgery . J. Biomed. Res.28 ( 2 ), 108 – 113 ( 2014 ).
   PubMedGoogle Scholar
• Lev EI , PatelRT , MareshKJet al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance . J. Am. Coll. Cardiol.47 ( 1 ), 27 – 33 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Navarese EP , AndreottiF , SchulzeVet al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents: meta-analysis of randomised controlled trials . BMJ350 , h1618 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Helft G , StegPG , Le FeuvreCet al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial . Eur. Heart J.37 ( 4 ), 365 – 374 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Levine GN , BatesER , BittlJAet al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines . J. Am. Coll. Cardiol.134 ( 10 ), e123 – e155 ( 2016 ).
   Google Scholar
• Bonello L , TantryUS , MarcucciRet al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate . J. Am. Coll. Cardiol.56 ( 12 ), 919 – 933 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Price MJ , BergerPB , TeirsteinPSet al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial . JAMA305 ( 11 ), 1097 – 1105 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Collet J-P , CuissetT , RangéGet al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting . N. Engl. J. Med.367 ( 22 ), 2100 – 2109 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Cayla G , CuissetT , SilvainJet al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial . Lancet388 ( 10055 ), 2015 – 2022 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Brar SS , Ten BergJ , MarcucciRet al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data . J. Am. Coll. Cardiol.58 ( 19 ), 1945 – 1954 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Tantry US , BonelloL , AradiDet al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding . J. Am. Coll. Cardiol.62 ( 24 ), 2261 – 2273 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Stone GW , WitzenbichlerB , WeiszGet al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study . Lancet382 ( 9892 ), 614 – 623 ( 2017 ).
   Google Scholar